Transparency of clinical trials data
This document contains an overview of current rules on access to clinical trials data, an overview of the anticipated legislative changes and a summary of the issues that the new regulation may bring, including concerns raised by the industry. This is an area of considerable interest to the industry at large and to many clients, and is one that Allen & Overy is following in detail.
Information on clinical trials is accessible to the public through the EU Clinical Trials Register website, launched by the European Medicines Agency (EMA). The register provides public access to the following information: interventional adult clinical trials for medicines, phase II to phase IV, which were authorised in the EU member states or the EEA; and clinical trials authorised to be carried out outside the EU if these trials are part of a paediatric investigation plan.
Specifically, the register contains information on trial identification, identification of the sponsor, information on each investigational medicinal product, information on placebo, objective, scope, trial type and phase and design of the trial. The information available dates back to 2004…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
A new Luxembourg act on the immobilisation of bearer shares and units was published in the Luxembourg Official Gazette on 14 August 2014.
OFAC has issued revised guidance relating to the status of entities owned by individuals or entities whose interests in property are blocked under executive orders.
Analysis from The Lawyer
At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.